RBC Capital Maintains Outperform on Xenon Pharmaceuticals, Raises Price Target to $82

RBC Capital analyst Brian Abrahams maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Outperform and raises the price target from $80 to $82.